Regarding the Adoption of Public Offering for “the Project that Establish Biopharmaceutical Manufacturing Bases to Strengthen Vaccine Production Structure” Led by the Ministry of Economy, Trade and Industry
Shionogi and its subsidiaries Shionogi Pharma and UMN Pharma have been pursuing the development of a recombinant protein vaccine using a unique technology BEVS*, and have been establishing the vaccine manufacturing structure, including scale-up for commercial use. We will use the subsidy from this project to construct a new vaccine formulation plants on the premises of Shionogi Pharma's Settsu Plant, thereby strengthening its production capabilities and building further preparations for future crises.
* Baculovirus Expression Vector System: Protein expression technology using insect cell-derived
[Summary of adoption]
Subject of development subsidy |
Development of formulation/filling bases |
Companies receiving subsidies |
Shionogi Pharma Co., Ltd. |
Place of the project |
Settsu City, Osaka (Shionogi Pharma Settsu Plant) |
Adoption date |
September 20, 2023 |
References
https://www.meti.go.jp/information/publicoffer/kobo/2023/k230317001.html (Only Japanese)
■ About Shionogi Pharma Co., Ltd.
■ UMN Pharma Inc.
For Further Information, Contact:
SHIONOGI Website Inquiry Form : https://www.shionogi.com/global/en/contact.html